These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 26385858)

  • 1. Facilitating Structure-Function Studies of CFTR Modulator Sites with Efficiencies in Mutagenesis and Functional Screening.
    Molinski SV; Ahmadi S; Hung M; Bear CE
    J Biomol Screen; 2015 Dec; 20(10):1204-17. PubMed ID: 26385858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.
    Brewington JJ; McPhail GL; Clancy JP
    Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptomic and Proteostasis Networks of CFTR and the Development of Small Molecule Modulators for the Treatment of Cystic Fibrosis Lung Disease.
    Strub MD; McCray PB
    Genes (Basel); 2020 May; 11(5):. PubMed ID: 32414011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CFTR protein repair therapy in cystic fibrosis.
    Quintana-Gallego E; Delgado-Pecellín I; Calero Acuña C
    Arch Bronconeumol; 2014 Apr; 50(4):146-50. PubMed ID: 24095197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of synergistic combinations of F508del cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
    Lin S; Sui J; Cotard S; Fung B; Andersen J; Zhu P; El Messadi N; Lehar J; Lee M; Staunton J
    Assay Drug Dev Technol; 2010 Dec; 8(6):669-84. PubMed ID: 21050065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of a Yellow fluorescent protein-based iodide influx high-throughput screening assay for cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
    Sui J; Cotard S; Andersen J; Zhu P; Staunton J; Lee M; Lin S
    Assay Drug Dev Technol; 2010 Dec; 8(6):656-68. PubMed ID: 21050066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combination therapy for cystic fibrosis.
    Brodsky JL; Frizzell RA
    Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic update in cystic fibrosis].
    Durupt S; Nove Josserand R; Durieu I
    Rev Med Interne; 2014 Jun; 35(6):388-92. PubMed ID: 24309546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystic Fibrosis: A Novel Pharmacologic Approach to Cystic Fibrosis Transmembrane Regulator Modulation Therapy.
    Virant-Young D; Thomas J; Woiderski S; Powers M; Carlier J; McCarty J; Kupchick T; Larder A
    J Am Osteopath Assoc; 2015 Sep; 115(9):546-55. PubMed ID: 26322933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. G551D and G1349D, two CF-associated mutations in the signature sequences of CFTR, exhibit distinct gating defects.
    Bompadre SG; Sohma Y; Li M; Hwang TC
    J Gen Physiol; 2007 Apr; 129(4):285-98. PubMed ID: 17353351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies.
    Antoniu SA
    Expert Opin Investig Drugs; 2011 Mar; 20(3):423-5. PubMed ID: 21303308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ivacaftor potentiation of multiple CFTR channels with gating mutations.
    Yu H; Burton B; Huang CJ; Worley J; Cao D; Johnson JP; Urrutia A; Joubran J; Seepersaud S; Sussky K; Hoffman BJ; Van Goor F
    J Cyst Fibros; 2012 May; 11(3):237-45. PubMed ID: 22293084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic rearrangements in the CFTR gene: extensive allelic heterogeneity and diverse mutational mechanisms.
    Audrézet MP; Chen JM; Raguénès O; Chuzhanova N; Giteau K; Le Maréchal C; Quéré I; Cooper DN; Férec C
    Hum Mutat; 2004 Apr; 23(4):343-57. PubMed ID: 15024729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ivacaftor as salvage therapy in a patient with cystic fibrosis genotype F508del/R117H/IVS8-5T.
    Carter S; Kelly S; Caples E; Grogan B; Doyle J; Gallagher CG; McKone EF
    J Cyst Fibros; 2015 Jul; 14(4):e4-5. PubMed ID: 25698453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct interaction of a small-molecule modulator with G551D-CFTR, a cystic fibrosis-causing mutation associated with severe disease.
    Pasyk S; Li C; Ramjeesingh M; Bear CE
    Biochem J; 2009 Feb; 418(1):185-90. PubMed ID: 18945216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms.
    Roxo-Rosa M; Xu Z; Schmidt A; Neto M; Cai Z; Soares CM; Sheppard DN; Amaral MD
    Proc Natl Acad Sci U S A; 2006 Nov; 103(47):17891-6. PubMed ID: 17098864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
    Jones AM; Barry PJ
    Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.